PB1902: FIRST EUROPEAN REAL-WORLD EVIDENCE PROSPECTIVE REGISTRY OF TAGRAXOFUSP, A CD123-DIRECTED THERAPY, FOR THE TREATMENT OF FIRST-LINE ADULT PATIENTS WITH BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM

Slični predmeti

• P529: FIRST EUROPEAN REAL-WORLD EVIDENCE PROSPECTIVE REGISTRY OF FIRST-LINE ADULT PATIENTS WITH BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM TREATED WITH FIRST-IN-CLASS CD123-TARGETED THERAPY TAGRAXOFUSP
  od: U. Platzbecker, i dr.
  Izdano: (2022-06-01)
• Tagraxofusp for blastic plasmacytoid dendritic cell neoplasm
  od: Marlise R. Luskin, i dr.
  Izdano: (2023-03-01)
• P521: TREATMENT OF BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM IN PEDIATRIC PATIENTS WITH TAGRAXOFUSP, A CD123-TARGETED THERAPY
  od: N. Pemmaraju, i dr.
  Izdano: (2022-06-01)
• P531: AN OBSERVATIONAL, MULTICENTER, RETROSPECTIVE ANALYSIS OF PATIENTS WITH BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM TREATED WITH TAGRAXOFUSP IN THE EUROPEAN EXPANDED ACCESS PROGRAM
  od: M. Herling, i dr.
  Izdano: (2022-06-01)
• Treatment of leptomeningeal disease in blastic plasmacytoid dendritic cell neoplasm following tagraxofusp-erzs induction
  od: Deepak B. Vangala, i dr.
  Izdano: (2022-04-01)